Too often, companies delay commercial strategy until late-stage development, assuming it’s a downstream task. However, the vast majority, 80–90% of drugs in development, must prioritize biotech commercial planning much earlier than they think. Delaying commercial readiness can create compounding risks that threaten your funding, your timeline, and your launch success.
Here’s what’s at stake when biotech commercial planning gets pushed too far down the road.
1. Reduced Investor or Acquirer Interest
Investors and acquirers today expect a robust early commercial strategy to accompany your clinical plan. Without a compelling commercial narrative, you risk being overlooked in favor of competitors who can clearly demonstrate product-market fit and growth potential.
Biotech companies that delay commercial planning often struggle to:
- Secure critical funding.
- Attract interest from potential acquirers or partners.
- Build credibility with key stakeholders.
Biotech commercial planning isn’t a nice-to-have; it’s a prerequisite for investor confidence.
2. Misalignment with Market, Patients, and Payers
If you wait too long to engage commercial functions, your development path may overlook critical market factors:
- Is your product differentiated enough?
- Will payers reimburse it?
- Are you solving a true unmet need?
Without early insights from market research and payer engagement, you risk launching a product that doesn’t resonate, or worse, one that doesn’t get covered.
3. Launch Delays
A delayed start to commercial planning in biotech often creates major gaps:
- Incomplete market understanding.
- Lack of secondary data to support claims.
- Underdeveloped KOL or HCP engagement plans.
These gaps can delay your biotech product launch by months or even years, ultimately reducing the product’s lifetime value and competitive edge.
4. Costly Last-Minute Changes
When commercial needs come into focus late, the resulting pivots are often expensive:
- Retrofitting clinical trials.
- Rushing to collect new data.
- Overhauling messaging or branding at the eleventh hour.
All of these emergency efforts drive up costs and reduce launch efficiency. By contrast, early biotech commercial planning allows you to integrate commercial considerations from the outset: saving time, money, and resources.
5. Underperformance at Launch
Studies show that only 20–30% of first-time launchers meet or exceed commercial expectations. Why? It’s rarely the science. More often, it’s the absence of a well-structured, realistic commercial plan.
Companies that invest in commercial readiness early are far better equipped to:
- Navigate payer negotiations.
- Educate physicians and patients.
- Build internal capabilities that support long-term growth.
The Takeaway: Plan Early, Win Bigger
If you’re not developing a first-in-class or ultra-orphan drug, the market won’t give you much breathing room. For most companies, biotech commercial planning should begin in Phase 2 or earlier, not post-approval.
By prioritizing early market insight, stakeholder alignment, and strategic planning, your team can reduce risk and maximize the return on years of clinical effort.
Need guidance on when and how to start your biotech commercial planning?
Our team specializes in helping biopharma teams build commercial strategies that scale with development. Connect with us today.